XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis.

ABSTRACT:

Background

Peripheral T-cell lymphoma (PTCL) is a highly heterogeneous group of lymphoid malignancies with diverse pathological and molecular features. Patients harboring TET2 and RHOA double mutations exhibit poor response to anthracycline-based chemotherapy and unfavorable prognosis. Azacitidine, a hypomethylating agent, is frequently used in combination with anthracycline-based regimens in PTCL. However, resistance remains a significant challenge. This study aims to explore novel targeted therapies to overcome therapeutic resistance in TET2/RHOA-mutated PTCL patients.

Methods

A systematic screen of 633 anti-tumor compounds was conducted to identify synergistic agents with azacitidine in TET2/RHOA-mutated cells. Cell viability assays, apoptosis analyses, and zebrafish xeno

SUBMITTER: Xu TT 

PROVIDER: S-EPMC12729132 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature